Səhifə 1 dan 32 nəticələr
FIELD OF THE INVENTION
This invention relates to remedies for prostate diseases, endometriosis and obesity comprising, as active ingredient, droloxifene having the chemical structure represented by the following formula, ##STR1## or a pharmaceutically acceptable salt thereof.
BACKGROUND OF THE
CROSS-REFERENCE TO RELATED APPLICATIONS
This U.S. patent application is a national stage application under 35 U.S.C. .sctn.371 of international application PCT/ES2013/070309, filed May 16, 2013, and claims the benefit of priority under 35 U.S.C. .sctn.119 of Spanish Patent Application No. 201230796,
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY
The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: MIRG.sub.--022.sub.--01WO_SeqList_ST25.txt, date recorded:
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto.
BACKGROUND OF THE INVENTION
The estrogen hormone has a broad spectrum of effects on tissues in
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto.
BACKGROUND OF THE INVENTION
The estrogen hormone has a broad spectrum of effects on tissues in
FIELD OF THE INVENTION
The present invention is directed generally to the field of treatment of obesity and other disorders characterized by proliferation of normal vascularized tissues, by the administration of effective amount of angiogenesis inhibitors.
BACKGROUND OF THE INVENTION
The prevalence
BACKGROUND
The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes, such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents
BACKGROUND
The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity, as well as to pharmaceutical compositions and methods
FIELD OF THE INVENTION
This invention relates to pyridoxine phosphonate analogues, to pyridoxine malonate analogues, to their preparation, to pharmaceutical compositions thereof, and to treatments for cardiovascular and related diseases, for example, hypertrophy, hypertension, congestive heart